Sirona Biochem (Seite 3098)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 08.05.24 17:10:08 von
neuester Beitrag 08.05.24 17:10:08 von
Beiträge: 31.047
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 159
Gesamt: 5.404.237
Gesamt: 5.404.237
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0450
EUR
-2,17 %
-0,0010 EUR
Letzter Kurs 15:45:57 Tradegate
Neuigkeiten
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,688 | +41,55 | |
| 2,5150 | +37,73 | |
| 2,9250 | +35,73 | |
| 1,0000 | +31,56 | |
| 3,8900 | +26,55 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0639 | -16,13 | |
| 1,5400 | -16,30 | |
| 0,5601 | -17,02 | |
| 7,5000 | -18,92 | |
| 0,5350 | -20,15 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 46.187.905 von Jon_Schnee am 09.01.14 08:12:38The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
-> Nach PP sollten die Kosten für Hauptquatier (Kanada) & Labor (Frankreich) gedeckt sein. Das nehmen wir bei Wort!
Inkl. Ausbau der Mitarbeiter im Labor -> 28 Mitarbeiter.
D.h. ein massiver Ausbau im Labour von 8 Mitarbeiter auf 28!!!
Quick Facts
• Employees
• Vancouver - 6
• France - 8
-> Nach PP sollten die Kosten für Hauptquatier (Kanada) & Labor (Frankreich) gedeckt sein. Das nehmen wir bei Wort!
Inkl. Ausbau der Mitarbeiter im Labor -> 28 Mitarbeiter.
D.h. ein massiver Ausbau im Labour von 8 Mitarbeiter auf 28!!!
Quick Facts
• Employees
• Vancouver - 6
• France - 8
Antwort auf Beitrag Nr.: 46.110.831 von Jon_Schnee am 25.12.13 08:41:35Wie vermutet / befürchtet braucht Sirona erneut Geld - schon ein wenig enttäuschend. Jetzt sind wir ca. bei 250 M Stück voll verwässert - mehr sollten nicht mehr dazu kommen - sonst Reissleine!
Sirona Biochem Announces CAD$5.3 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 8, 2014) -Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), (the "Company") announced today a non-brokered private placement of up to 33,400,000 units of the Company at a price of $0.16 CAD each (a "Unit") for gross proceeds of up to CAD$5,344,000 (the "Private Placement").
Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferable share purchase warrant (a complete warrant shall be referred to as a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for three years from the closing date of the Private Placement at a price of CAD$0.27 per Share.
The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants"). The Finder's Warrants will be exercisable into one-half of one additional Share of the Company at a price of CAD$0.27 per Share for a period of 3 years from the closing date of the Private Placement.
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSXV acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/01/08/sir…
Sirona Biochem Announces CAD$5.3 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 8, 2014) -Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), (the "Company") announced today a non-brokered private placement of up to 33,400,000 units of the Company at a price of $0.16 CAD each (a "Unit") for gross proceeds of up to CAD$5,344,000 (the "Private Placement").
Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferable share purchase warrant (a complete warrant shall be referred to as a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for three years from the closing date of the Private Placement at a price of CAD$0.27 per Share.
The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants"). The Finder's Warrants will be exercisable into one-half of one additional Share of the Company at a price of CAD$0.27 per Share for a period of 3 years from the closing date of the Private Placement.
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSXV acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/01/08/sir…
Offenes Haus - wer am 10 Januar in Vancouver ist:
Gerne vorbei gehen - und hier Berichten
Ich hoffe sie schlissen davor 1 oder 2 Verträge ab - den viele Anleger sind langsam ungeduldig - ich auch - damit die Open House Party wirklich eine Party wird!
Sirona Biochem Open House
Zeitpunkt Fr 10. Jan. 2014 20:00 – 23:00 (MEZ)
Wo Sirona Biochem: Sirona Biochem 605-889 W Pender St Vancouver, BC V6C 3B2
Gerne vorbei gehen - und hier Berichten
Ich hoffe sie schlissen davor 1 oder 2 Verträge ab - den viele Anleger sind langsam ungeduldig - ich auch - damit die Open House Party wirklich eine Party wird!
Sirona Biochem Open House
Zeitpunkt Fr 10. Jan. 2014 20:00 – 23:00 (MEZ)
Wo Sirona Biochem: Sirona Biochem 605-889 W Pender St Vancouver, BC V6C 3B2
Local company harnesses anti-aging properties of Antarctic fish antifreeze protein for global market
Sirona Biochem's discoveries attract attention from global cosmetics giant L'Oréal and Cincinnati Children's Hospital
http://www.biv.com/article/20131223/BIV0112/312109893/-1/BIV…...
Sirona Biochem's discoveries attract attention from global cosmetics giant L'Oréal and Cincinnati Children's Hospital
http://www.biv.com/article/20131223/BIV0112/312109893/-1/BIV…...
Antwort auf Beitrag Nr.: 46.111.473 von dottore am 25.12.13 13:45:05Ciao Dottore
Ja, Sirona ist kein easy Investment. Sind Biotech Firmen nie und schon gar keine Biotech Klitschen.
Wo würdest Du gerne investieren? Tipps sind immer willkomen
gerne hier.
oder noch besser hier posten:
http://www.wallstreet-online.de/diskussion/1186055-neustebei…
Antwort wäre Klasse
Ja, Sirona ist kein easy Investment. Sind Biotech Firmen nie und schon gar keine Biotech Klitschen.
Wo würdest Du gerne investieren? Tipps sind immer willkomen
gerne hier.
oder noch besser hier posten:
http://www.wallstreet-online.de/diskussion/1186055-neustebei…
Antwort wäre Klasse
Trading Spotlight
sehr schwer einzuschätzen. Gleichzeitig gibt es eine Reihe anderer Investmöglichkeiten, die mir mehr bei weniger Aufwand versprechen.
Ich glAUBE NICHT; DASS ICH HIER EINSTEIGEN WERDE:
fINDE GUT; DASS DU selbst distanziert schreibst und nicht blind puschst.
Finde die kritischen Beiträge von DJ etwas zu persönlich angreifend.
Viel Glück hier, besser: Investier wo anders!
Ich glAUBE NICHT; DASS ICH HIER EINSTEIGEN WERDE:
fINDE GUT; DASS DU selbst distanziert schreibst und nicht blind puschst.
Finde die kritischen Beiträge von DJ etwas zu persönlich angreifend.
Viel Glück hier, besser: Investier wo anders!
Antwort auf Beitrag Nr.: 46.110.831 von Jon_Schnee am 25.12.13 08:41:35Grösste Fanatasie derzeit sicher bei Skin Lightening
http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-…
2 ähnlihce Wirkstoffe:
TFC-849: Gib's ein LOI ->
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.sironabiochem.com/sirona-biochem-signs-letter-of-…
Obagi wurde von Valenat übernommen:
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
Valeant Pharmaceuticals International, Inc. (VRX) -NYSE
Kurs: 113 USD / Market Cap: 37.74B / Revenue (ttm): 4.69B
VALEANT ist also kein kleines Unternehmen.
-> hier hoffe ich bei Unterschrift auf eine erste Milestone Zahlung.
Wenn das nicht passiert -> neue Verwässerung!!!
and TFC-723: ??? Hoffe auf einen anderen Major
http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-…
2 ähnlihce Wirkstoffe:
TFC-849: Gib's ein LOI ->
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.sironabiochem.com/sirona-biochem-signs-letter-of-…
Obagi wurde von Valenat übernommen:
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
Valeant Pharmaceuticals International, Inc. (VRX) -NYSE
Kurs: 113 USD / Market Cap: 37.74B / Revenue (ttm): 4.69B
VALEANT ist also kein kleines Unternehmen.
-> hier hoffe ich bei Unterschrift auf eine erste Milestone Zahlung.
Wenn das nicht passiert -> neue Verwässerung!!!
and TFC-723: ??? Hoffe auf einen anderen Major
Antwort auf Beitrag Nr.: 46.109.615 von dottore am 24.12.13 13:55:41Ciao Dottore
gerngesehen - Der Thread ist zu einem Tagebuch resp. Info Sammlung verkommen als zu einer Diskussion Plattform. Anscheinend kein Interesse in Deutschland an Sirona. Na Ja, nicht desto trotz ist das kleine Ding in 2013 um 66% gestiegen Und ist jetzt ca. 30Mio CAD schwer.
Es gibt durchaus Intresse an der Plattform http://www.sironabiochem.com/ von Sirona:
siehe Diverse LOI "Letter of Intent" : http://www.sironabiochem.com/sirona-biochem-corporation-ceos…" target="_blank" rel="nofollow ugc noopener">http://www.sironabiochem.com/sirona-biochem-corporation-ceos…
Bis jetzt kam es aber nur zu einem Vertrag durch einen solchen LOI:
Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.com/news/press-releases/2013/12/04/sir…
-> Langfristig sicher eine gute Sache.
Jedoch löst es das GROSSE PROBLEM von Sirona derzeit nicht.
Und hier liegt der Hund begraben.
Finanzierung: Company ist recht klamm. Wenn nicht bald ein neuer Vertrag unterschrieben wird heisst das erneut Verwässerung. Evt. auch mit Vertrag.
und es sind schon 200M Aktien drausen.
Potential ist riesig bei Sirona:
http://www.sironabiochem.com/products/pipeline/
Besonders der Kosmetik Bereich -> Skin Lightening / Anti Aging
Langfristig aber der Pharma Bereich.
Mit einem Kurs von 0.15 CAD hängt man ein wenig in der Luft für einen neuen Einstieg finde ich:
Wenn eine Finanzierung kommt ohne gute News dazu oder die Märkte einbrechen geht's vermutlich wieder schnell Richtung 0.12 CAD oder tiefer.
Wenn jedoch all die LOI in Verträge Zeitnah umgewandelt werden kann es durchaus schnell raufgehen.
So das sind meine Überlegungen. Deine?
Schöne Festtage noch
gerngesehen - Der Thread ist zu einem Tagebuch resp. Info Sammlung verkommen als zu einer Diskussion Plattform. Anscheinend kein Interesse in Deutschland an Sirona. Na Ja, nicht desto trotz ist das kleine Ding in 2013 um 66% gestiegen
Und ist jetzt ca. 30Mio CAD schwer.Es gibt durchaus Intresse an der Plattform http://www.sironabiochem.com/ von Sirona:
siehe Diverse LOI "Letter of Intent" : http://www.sironabiochem.com/sirona-biochem-corporation-ceos…" target="_blank" rel="nofollow ugc noopener">http://www.sironabiochem.com/sirona-biochem-corporation-ceos…
Bis jetzt kam es aber nur zu einem Vertrag durch einen solchen LOI:
Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.com/news/press-releases/2013/12/04/sir…
-> Langfristig sicher eine gute Sache.
Jedoch löst es das GROSSE PROBLEM von Sirona derzeit nicht.
Und hier liegt der Hund begraben.
Finanzierung: Company ist recht klamm. Wenn nicht bald ein neuer Vertrag unterschrieben wird heisst das erneut Verwässerung. Evt. auch mit Vertrag.
und es sind schon 200M Aktien drausen.
Potential ist riesig bei Sirona:
http://www.sironabiochem.com/products/pipeline/
Besonders der Kosmetik Bereich -> Skin Lightening / Anti Aging
Langfristig aber der Pharma Bereich.
Mit einem Kurs von 0.15 CAD hängt man ein wenig in der Luft für einen neuen Einstieg finde ich:
Wenn eine Finanzierung kommt ohne gute News dazu oder die Märkte einbrechen geht's vermutlich wieder schnell Richtung 0.12 CAD oder tiefer.
Wenn jedoch all die LOI in Verträge Zeitnah umgewandelt werden kann es durchaus schnell raufgehen.
So das sind meine Überlegungen. Deine?
Schöne Festtage noch
@Jon_Schnee danke für Info und deine Ausdauer
Dass in all den Monaten hier so wenig Resonanz zu finden war, ändert nichts daran, dass der Kurs sich in der gleichen Zeit in etwa verdoppelt hat.
Trotz allem fällt es mir schwer, ein Urteil zu finden. Lohnt sich ein Invest, oder doch nicht? Der Kurs ist ja schon gewaltig gestiegen ....
Und wenn ich das mit der Kapitalerhöhung richtig verstanden habe, dann sind jetzt rund 200 Mio Aktien da, somit eine Marktkapitalisierung von etwa 30 Mio Cad $
Immer noch wenig.
Wenn so viel dran wär, wie du glaubst, wieso kommt kein anderer drauf und warum steht die Aktie nicht bei 1 $?
Dass in all den Monaten hier so wenig Resonanz zu finden war, ändert nichts daran, dass der Kurs sich in der gleichen Zeit in etwa verdoppelt hat.
Trotz allem fällt es mir schwer, ein Urteil zu finden. Lohnt sich ein Invest, oder doch nicht? Der Kurs ist ja schon gewaltig gestiegen ....
Und wenn ich das mit der Kapitalerhöhung richtig verstanden habe, dann sind jetzt rund 200 Mio Aktien da, somit eine Marktkapitalisierung von etwa 30 Mio Cad $
Immer noch wenig.
Wenn so viel dran wär, wie du glaubst, wieso kommt kein anderer drauf und warum steht die Aktie nicht bei 1 $?
Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a joint venture to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Sirona and Bloom Burton will identify and design numerous different anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry, using its proprietary expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds. At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. With the former, often overlooked and the latter, an emerging threat, the collaboration between Sirona and Bloom Burton will endeavor to help minimize the medical gap by maximizing on each of the companies' core competencies.
"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking" said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, President of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Antonia Issa
Communications Manager
Sirona Biochem Corp.
1.604.282.6065
aissa@sironabiochem.com
Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a joint venture to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Sirona and Bloom Burton will identify and design numerous different anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry, using its proprietary expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds. At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. With the former, often overlooked and the latter, an emerging threat, the collaboration between Sirona and Bloom Burton will endeavor to help minimize the medical gap by maximizing on each of the companies' core competencies.
"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking" said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, President of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Antonia Issa
Communications Manager
Sirona Biochem Corp.
1.604.282.6065
aissa@sironabiochem.com
Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…
Durchsuchen
Sirona Biochem
